RS68293B1 - Lečenje alchajmerove bolesti kod specifične populacije pacijenata - Google Patents
Lečenje alchajmerove bolesti kod specifične populacije pacijenataInfo
- Publication number
- RS68293B1 RS68293B1 RS20260811A RSP20260811A RS68293B1 RS 68293 B1 RS68293 B1 RS 68293B1 RS 20260811 A RS20260811 A RS 20260811A RS P20260811 A RSP20260811 A RS P20260811A RS 68293 B1 RS68293 B1 RS 68293B1
- Authority
- RS
- Serbia
- Prior art keywords
- subject
- apoe4
- pharmaceutical composition
- tramiprosate
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Patentni zahtevi
1. Farmaceutska kompozicija koja sadrži tramiprozat, valil-3-amino-1-propansulfonsku kiselinu ili njenu farmaceutski prihvatljivu so namenjena za upotrebu u postupku lečenja Alchajmerove bolesti kod ispitanika koji
(i) je APOE4+, i
(ii) ima početnu ocenu na mini proceni mentalnog stanja (MMSE) 16-19 u roku od šezdeset dana pre prve primene kompozicije.
2. Farmaceutska kompozicija za upotrebu iz zahteva 1, pri čemu postupak obuhvata primenu 150 mg BID tramiprozata, 265 mg BID valil-3-amino-1-propansulfonske kiseline ili ekvivalentne količine njene farmaceutski prihvatljive soli.
3. Farmaceutska kompozicija za upotrebu iz zahteva 1, pri čemu farmaceutska kompozicija isporučuje dozu tramiprozata u rasponu od 100 mg-150 mg/dozi.
4. Farmaceutska kompozicija za upotrebu iz zahteva 3, pri čemu farmaceutska kompozicija sadrži od 260 mg do 270 mg valil-3-amino-1-propansulfonske kiseline ili njene farmaceutski prihvatljive soli, i pri čemu je kompozicija formulisana kao kompozicija sa trenutnim oslobađanjem, oralna tableta ili kapsula.
5. Farmaceutska kompozicija za upotrebu prema zahtevu 4, pri čemu kompozicija sadrži 265 mg valil-3-amino-1-propansulfonske kiseline.
6. Farmaceutska kompozicija za upotrebu prema bilo kom od zahteva 1 i 3-5, pri čemu se farmaceutska kompozicija primenjuje dva puta dnevno.
7. Farmaceutska kompozicija za upotrebu prema bilo kom od zahteva 1-6, pri čemu ispitanik ima 85 godina ili manje.
8. Farmaceutska kompozicija za upotrebu prema bilo kom od zahteva 1-7, pri čemu lečenje smanjuje kognitivno propadanje kod ispitanika.
9. Farmaceutska kompozicija za upotrebu prema bilo kom od zahteva 1-8, pri čemu je početna MMSE ocena dobijena u roku od trideset dana pre prve primene kompozicije.
10. Farmaceutska kompozicija za upotrebu prema bilo kom od zahteva 1-9, pri čemu je ispitanik APOE4/4 homozigotan.
11. Farmaceutska kompozicija za upotrebu prema bilo kom od zahteva 1-9, pri čemu je ispitanik APOE4 heterozigotan.
12. Postupak za određivanje ispitanikove podobnosti za lečenje tramiprozatom, valil-3-amino-1-propansulfonskom kiselinom ili njenom farmaceutski prihvatljivom solju koji obuhvata utvrđivanje APOE4 statusa ispitanika i utvrđivanje težine Alchajmerove bolesti kod ispitanika, pri čemu, ako je ispitanik APOE4<+>i ima početnu MMSE ocenu 16-19, smatra se da je ispitanik podoban za ovo lečenje.
13. Postupak iz zahteva 12, pri čemu je utvrđeno da je ispitanik podoban za lečenje sa 150 mg BID tramiprozata ili 265 mg BID valil-3-amino-1-propansulfonske kiseline, ili njenom farmaceutski prihvatljivom solju.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216404P | 2015-09-10 | 2015-09-10 | |
| US201662290287P | 2016-02-02 | 2016-02-02 | |
| US201662302027P | 2016-03-01 | 2016-03-01 | |
| US201662365809P | 2016-07-22 | 2016-07-22 | |
| EP23176559.5A EP4275750B1 (en) | 2015-09-10 | 2016-09-09 | Treatment of alzheimer's disease in a particular patient population |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS68293B1 true RS68293B1 (sr) | 2026-07-31 |
Family
ID=58240195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20260811A RS68293B1 (sr) | 2015-09-10 | 2016-09-09 | Lečenje alchajmerove bolesti kod specifične populacije pacijenata |
| RS20230603A RS64481B1 (sr) | 2015-09-10 | 2016-09-09 | Lečenje alchajmerove bolesti kod posebne populacije pacijenata |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230603A RS64481B1 (sr) | 2015-09-10 | 2016-09-09 | Lečenje alchajmerove bolesti kod posebne populacije pacijenata |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11191742B2 (sr) |
| EP (2) | EP3347002B1 (sr) |
| JP (4) | JP6789579B2 (sr) |
| KR (2) | KR102412997B1 (sr) |
| CN (3) | CN116712423A (sr) |
| AU (1) | AU2016319107B2 (sr) |
| CA (1) | CA2997376C (sr) |
| DK (1) | DK3347002T3 (sr) |
| ES (1) | ES2952727T3 (sr) |
| FI (1) | FI3347002T3 (sr) |
| HR (1) | HRP20230809T1 (sr) |
| HU (1) | HUE062511T2 (sr) |
| LT (1) | LT3347002T (sr) |
| MD (1) | MD3347002T2 (sr) |
| MX (2) | MX392677B (sr) |
| PL (1) | PL3347002T3 (sr) |
| PT (1) | PT3347002T (sr) |
| RS (2) | RS68293B1 (sr) |
| SI (1) | SI3347002T1 (sr) |
| SM (2) | SMT202300250T1 (sr) |
| WO (1) | WO2017044840A1 (sr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2960625T3 (es) | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| CN114805211B (zh) | 2017-03-21 | 2024-08-23 | 润佳（苏州）医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| MX2021001287A (es) * | 2018-08-01 | 2021-07-15 | Alzheon Inc | Métodos para tratar trastornos neurodegenerativos. |
| SI4296670T1 (sl) * | 2018-08-01 | 2026-04-30 | Alzheon, Inc. | Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| PH12021553196A1 (en) * | 2019-06-17 | 2022-11-07 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| AU2022405026A1 (en) * | 2021-12-09 | 2024-06-20 | Alzheon, Inc. | Alz-801 for use in treating alzheimer's disease |
| WO2023150381A1 (en) * | 2022-02-07 | 2023-08-10 | Alzheon, Inc. | Alz-801 for use in treating a covid-19 associated neurological symptom |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| CA2142300C (en) | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| EP1664601B1 (en) | 2003-08-11 | 2016-10-12 | California Institute Of Technology | Microfluidic large scale integration |
| US20060251714A1 (en) * | 2005-04-12 | 2006-11-09 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| SI2089417T1 (sl) | 2006-10-12 | 2015-04-30 | Bhi Limited Partnership | Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline |
| SG173409A1 (en) | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US20120009125A1 (en) | 2010-07-06 | 2012-01-12 | Lombard Jay L | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| MX353096B (es) | 2010-08-19 | 2017-12-19 | Buck Institute For Age Res Star | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
| US20150118231A1 (en) * | 2012-05-08 | 2015-04-30 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| HUE044737T2 (hu) * | 2013-05-06 | 2019-11-28 | Baxalta Inc | Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel |
| NZ723884A (en) | 2014-02-08 | 2023-02-24 | Genentech Inc | Methods of treating alzheimer’s disease |
| ES2960625T3 (es) * | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
-
2016
- 2016-09-09 EP EP16845181.3A patent/EP3347002B1/en active Active
- 2016-09-09 PL PL16845181.3T patent/PL3347002T3/pl unknown
- 2016-09-09 SM SM20230250T patent/SMT202300250T1/it unknown
- 2016-09-09 ES ES16845181T patent/ES2952727T3/es active Active
- 2016-09-09 RS RS20260811A patent/RS68293B1/sr unknown
- 2016-09-09 MD MDE20180700T patent/MD3347002T2/ro unknown
- 2016-09-09 WO PCT/US2016/051091 patent/WO2017044840A1/en not_active Ceased
- 2016-09-09 DK DK16845181.3T patent/DK3347002T3/da active
- 2016-09-09 SI SI201631729T patent/SI3347002T1/sl unknown
- 2016-09-09 KR KR1020187009381A patent/KR102412997B1/ko active Active
- 2016-09-09 US US15/758,405 patent/US11191742B2/en active Active
- 2016-09-09 JP JP2018512564A patent/JP6789579B2/ja active Active
- 2016-09-09 HU HUE16845181A patent/HUE062511T2/hu unknown
- 2016-09-09 LT LTEPPCT/US2016/051091T patent/LT3347002T/lt unknown
- 2016-09-09 AU AU2016319107A patent/AU2016319107B2/en active Active
- 2016-09-09 CN CN202310582394.5A patent/CN116712423A/zh active Pending
- 2016-09-09 HR HRP20230809TT patent/HRP20230809T1/hr unknown
- 2016-09-09 RS RS20230603A patent/RS64481B1/sr unknown
- 2016-09-09 EP EP23176559.5A patent/EP4275750B1/en active Active
- 2016-09-09 MX MX2018003023A patent/MX392677B/es unknown
- 2016-09-09 FI FIEP16845181.3T patent/FI3347002T3/fi active
- 2016-09-09 KR KR1020227009418A patent/KR102547164B1/ko active Active
- 2016-09-09 CN CN201680052760.4A patent/CN108289870A/zh active Pending
- 2016-09-09 PT PT168451813T patent/PT3347002T/pt unknown
- 2016-09-09 CN CN202310582365.9A patent/CN116712422A/zh active Pending
- 2016-09-09 CA CA2997376A patent/CA2997376C/en active Active
- 2016-09-09 SM SM20260257T patent/SMT202600257T1/it unknown
-
2018
- 2018-03-09 MX MX2022003128A patent/MX2022003128A/es unknown
-
2020
- 2020-09-28 JP JP2020161995A patent/JP7128536B2/ja active Active
-
2021
- 2021-09-17 US US17/477,886 patent/US20220096406A1/en not_active Abandoned
-
2022
- 2022-08-12 JP JP2022128786A patent/JP2022145949A/ja active Pending
-
2023
- 2023-09-06 US US18/462,238 patent/US20230414541A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023627A patent/JP2025065545A/ja active Pending